These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 12660532)
1. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. Calza L; Manfredi R; Chiodo F AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532 [TBL] [Abstract][Full Text] [Related]
2. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Calza L; Manfredi R; Chiodo F Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511 [TBL] [Abstract][Full Text] [Related]
3. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. Manfredi R; Chiodo F J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549 [TBL] [Abstract][Full Text] [Related]
4. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. Calza L; Manfredi R; Colangeli V; Tampellini L; Sebastiani T; Pocaterra D; Chiodo F AIDS; 2005 Jul; 19(10):1051-8. PubMed ID: 15958836 [TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Calza L; Manfredi R; Colangeli V; Pocaterra D; Pavoni M; Chiodo F Curr HIV Res; 2008 Nov; 6(6):572-8. PubMed ID: 18991624 [TBL] [Abstract][Full Text] [Related]
6. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Calza L; Manfredi R; Chiodo F Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947 [TBL] [Abstract][Full Text] [Related]
7. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F; HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977 [TBL] [Abstract][Full Text] [Related]
8. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079 [TBL] [Abstract][Full Text] [Related]
9. Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy. Geraix J; de Souza ME; Delatim FC; Pereira PC Braz J Infect Dis; 2006 Jun; 10(3):159-64. PubMed ID: 17568845 [TBL] [Abstract][Full Text] [Related]
10. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. Hirsch HH; Battegay M Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856 [TBL] [Abstract][Full Text] [Related]
11. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. Miller J; Brown D; Amin J; Kent-Hughes J; Law M; Kaldor J; Cooper DA; Carr A AIDS; 2002 Nov; 16(16):2195-200. PubMed ID: 12409741 [TBL] [Abstract][Full Text] [Related]
14. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878 [TBL] [Abstract][Full Text] [Related]
15. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Caramelli B; de Bernoche CY; Sartori AM; Sposito AC; Santos RD; Monachini MC; Strabelli T; Uip D Braz J Infect Dis; 2001 Dec; 5(6):332-8. PubMed ID: 11980596 [TBL] [Abstract][Full Text] [Related]
16. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403 [TBL] [Abstract][Full Text] [Related]
17. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642 [No Abstract] [Full Text] [Related]
18. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration. Manfredi R; Calza L; Chiodo F J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548 [TBL] [Abstract][Full Text] [Related]
19. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645 [TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]